To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have stage III or IV NSCLC with a fusion of the EML4 and ALK genes.
- Patients may not have previously received crizotinib, but may have had other chemotherapy.
- Patients should have recovered from the side effects of prior therapies before entering the study.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Gregory Riely at 646-888-4199.